A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (SURVEYOR-II)

Trial Profile

A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (SURVEYOR-II)

Completed
Phase of Trial: Phase II/III

Latest Information Update: 14 Apr 2018

At a glance

  • Drugs Glecaprevir (Primary) ; Glecaprevir/pibrentasvir (Primary) ; Pibrentasvir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Registrational; Therapeutic Use
  • Acronyms SURVEYOR-II
  • Sponsors AbbVie
  • Most Recent Events

    • 14 Apr 2018 Results of an integrated analysis of 10 studies (SURVEYOR-I, -II, MAGELLAN-I, ENDURANCE-1, -2, -3, -4, EXPEDITION-1, -2 and -4; n=789) assessing efficacy and safety in patients with psychiatric disorders, presented at The International Liver Congress 2018
    • 15 Mar 2018 Results (n=2041) of integrated efficacy analysis from EXPEDITION-2, EXPEDITION-4, ENDURANCE 1, 2, 3 and 4, SURVEYOR-I Part 2, SURVEYOR-II Parts 1 and 2, and SURVEYOR-II Part 4 studies published in the Journal of Hepatology
    • 24 Oct 2017 Results of an integrated analysis from ENDURANCE-1, ENDURANCE-2, ENDURANCE-3, ENDURANCE-4, EXPEDITION-1, EXPEDITION-4, SURVEYOR-II, and MAGELLAN-1 studies, presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top